Sun Pharma Advances $13 Billion Organon Acquisition Amid Global Expansion Strategy

Sun Pharma Submits Binding Offer for Organon & Co in Deal Worth Nearly $13 Billion

Dilip Shanghvi, the chairman of Sun Pharmaceutical Industries, is moving forward with what could become his biggest deal yet, with a binding offer of nearly $13 billion submitted for US-based Organon & Co, according to an Economic Times report. The proposed acquisition is part of Sun Pharma's broader push to evolve from an Indian generics leader into a global branded and innovation-driven drugmaker.

Sun Pharma, India's largest drugmaker by revenue and market value, is competing with Swedish private equity firm EQT and German pharmaceutical company Gruenthal in the race for Organon. Gruenthal is known for its focus on pain management therapies. Organon's shares had earlier fallen more than 19% after briefly rallying in January when news of Sun Pharma's interest first surfaced. The company's market capitalisation currently stands at about $2.4 billion on the NYSE.

Sun Pharma ended Thursday with a market valuation of around ₹4.03 lakh crore ($42.8 billion). The recent excitement around Organon's stock has shifted investor attention away from concerns such as debt levels and slower growth, and instead toward the value of its product portfolio, cash generation potential, and possible carve-out opportunities.

Read also: Finolex Industries Expected to Report 36.6% YoY Increase in Q4 Profit After Tax to Rs. 225.4 Crores: ICICI Securities

ET had first reported on January 19 that Sun Pharma was evaluating Organon, a debt-laden US drugmaker focused on women's health that was spun off from MSD (Merck Sharp & Dohme) in 2021. Later, on April 10, ET said Sun Pharma was preparing a final bid, a development that triggered a 29% rally in Organon's stock in the next trading session.

Sun Pharma and Organon did not respond to ET's queries, while EQT and Gruenthal declined to comment.

Any buyer of Organon would need to address the debt burden inherited from MSD. Organon ended 2025 with debt of $8.64 billion and has guided for 2026 revenue of $6.1 billion to $6.3 billion, compared with $6.4 billion reported in 2025.

Read also: TPG-Led Consortium to Acquire Aseem Infra Finance for Approximately 4,000 Crore Rupees

ET added that Sun Pharma's financing plan is largely centred on assuming Organon's debt. The Mumbai-based company also has net cash of about $3.2 billion (Rs 26,000 crore), which it may deploy toward purchasing Organon's equity. The total valuation would include the target's equity value, premium, and debt obligations.

In recent months, Shanghvi has emphasised the need for Indian pharmaceutical companies to invest in innovative research while retaining their strength in generics, and to consider acquisitions where necessary to build scale, ET said.

During FY26, Sun Pharma posted sales of around Rs 52,000 crore, with the US and India each contributing roughly 31% to 33% of revenue. The remainder came from other international markets and active pharmaceutical ingredients (APIs), ET reported.

Organon's portfolio is viewed as attractive because of its presence in women's health segments such as breast cancer, contraception, osteoporosis, and menopause, along with its biosimilars business.

EQT is among Europe's biggest investors in life sciences and pharmaceuticals. Earlier this year, it had opened talks with Oxford BioMedica regarding a possible acquisition but later withdrew, ET reported.

Gruenthal, which operates in 28 countries and has a presence in around 100 markets, reported revenue of €1.8 billion and adjusted EBITDA of €500 million in 2025. ET said the company has completed five acquisitions in five years across men's health, pain therapies, and branded medicines.

Since 2017, Gruenthal has spent more than $2 billion on acquisitions. Two of its largest transactions include the €550 million purchase of Nebido from Bayer and a $250 million deal for Valinor in the US, moves that marked a strategic expansion, ET added.